TwinStrand's biochemistry and software-based solution enables researchers and clinicians to detect genetic 'needles in a haystack.' By identifying ultra-low frequency DNA mutations with a resolution 10,000-fold greater than conventional tools on the market, TwinStrand enables detection, quantification, and characterization of variants that were previously undetectable.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/07/21 | $50,000,000 | Series B |
Alexandria Venture Investments Madrona Venture Group  Ridgeback Capital Management | undisclosed |
